Prostate cancer: Feasibility and preliminary experience of a diffusional kurtosis model for detection and assessment of aggressiveness of peripheral zone cancer

Radiology

Volumn 264, Issue 1, 2012, Pages 126-135

  Rosenkrantz, Andrew B ^a   Sigmund, Eric E ^a   Johnson, Glyn ^a   Babb, James S ^a   Mussi, Thais C ^a,b   Melamed, Jonathan ^a   Taneja, Samir S ^a   Lee, Vivian S ^a,c   Jensen, Jens H ^a,d  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CANCER GRADING; CANCER GROWTH; COHORT ANALYSIS; CONTROLLED STUDY; CORRECTED DIFFUSION; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DIFFUSIONAL KURTOSIS IMAGING; FEASIBILITY STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PHYSICAL PARAMETERS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO;

AGED; ANALYSIS OF VARIANCE; BAYES THEOREM; BIOPSY; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; FEASIBILITY STUDIES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; NEOPLASM GRADING; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 84862699477     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12112290     Document Type: Article

References (62)

1. Albertsen PC. Treatment of localized prostate cancer: when is active surveillance appropriate? Nat Rev Clin Oncol 2010;7(7):394-400.
2. Klotz L. Active surveillance for prostate cancer: a review. Curr Urol Rep 2010;11(3):165-171.
3. Ahmed HU, Emberton M. Is focal therapy the future for prostate cancer? Future Oncol 2010;6(2):261-268.
4. Mufarrij P, Sankin A, Godoy G, Lepor H. Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy. Urology 2010;76(3):689-692.
5. Anast JW, Andriole GL, Bismar TA, Yan Y, Humphrey PA. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004;64(3):544-550. (Pubitemid 39200755)
6. Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol 2009;192(6):1471-1480.
7. Gibbs P, Liney GP, Pickles MD, Zelhof B, Rodrigues G, Turnbull LW. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol 2009;44(9):572-576.
8. Vargas HA, Akin O, Franiel T, et al. Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology 2011;259(3):775-784.
9. Yoshimitsu K, Kiyoshima K, Irie H, et al. Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging 2008;27(1):132-139.
10. Tamada T, Sone T, Jo Y, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging 2008;28(3):720-726.
11. Verma S, Rajesh A, Morales H, et al. Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol 2011;196(2):374-381.
12. Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF 2nd. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol 2010;194(4):W316-W322.
13. Turkbey B, Shah VP, Pang Y, et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology 2011;258(2):488-495.
14. Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011;259(2):453-461.
15. van As NJ, de Souza NM, Riches SF, et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol 2009;56(6):981-987.
16. Park SY, Kim CK, Park BK, Lee HM, Lee KS. Prediction of biochemical recurrence following radical prostatectomy in men with prostate cancer by diffusion-weighted magnetic resonance imaging: initial results. Eur Radiol 2011;21(5):1111-1118.
17. Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 2011;59(4):477-494.
18. DeCarlo L. On the meaning and use of kurtosis. Psychol Methods 1997;2(3):292-307. (Pubitemid 127457333)
19. Jensen JH, Helpern JA, Ramani A, Lu H, Kaczynski K. Diffusional kurtosis imaging: the quantification of non-gaussian water diffusion by means of magnetic resonance imaging. Magn Reson Med 2005;53(6):1432-1440. (Pubitemid 40734665)
20. Lu H, Jensen JH, Ramani A, Helpern JA. Three-dimensional characterization of nongaussian water diffusion in humans using diffusion kurtosis imaging. NMR Biomed 2006;19(2):236-247.
21. Jensen JH, Helpern JA. MRI quantification of non-Gaussian water diffusion by kurtosis analysis. NMR Biomed 2010;23(7):698-710.
22. Raab P, Hattingen E, Franz K, Zanella FE, Lanfermann H. Cerebral gliomas: diffusional kurtosis imaging analysis of microstructural differences. Radiology 2010;254(3):876-881.
23. Tabesh A, Jensen JH, Ardekani BA, Helpern JA. Estimation of tensors and tensor-derived measures in diffusional kurtosis imaging. Magn Reson Med 2011;65(3):823-836.
24. Gürses B, Kabakci N, Kovanlikaya A, et al. Diffusion tensor imaging of the normal prostate at 3 Tesla. Eur Radiol 2008;18(4):716-721. (Pubitemid 351447776)
25. Xu J, Humphrey PA, Kibel AS, et al. Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans. Magn Reson Med 2009;61(4):842-850.
26. Jansen JF, Stambuk HE, Koutcher JA, Shukla-Dave A. Non-gaussian analysis of diffusion-weighted MR imaging in head and neck squamous cell carcinoma: a feasibility study. AJNR Am J Neuroradiol 2010;31(4):741-748.
27. Schwarz G. Estimating the dimension of a model. Ann Stat 1978;6(2):461-464.
28. Cornfeld DM, Israel G, McCarthy SM, Weinreb JC. Pelvic imaging using a T1W fat-suppressed three-dimensional dual echo Dixon technique at 3T. J Magn Reson Imaging 2008;28(1):121-127. (Pubitemid 351956474)
29. Hori M, Kim T, Onishi H, et al. Uterine tumors: comparison of 3D versus 2D T2-weighted turbo spin-echo MR imaging at 3.0 T-initial experience. Radiology 2011;258(1):154-163.
30. Shinmoto H, Oshio K, Tanimoto A, et al. Biexponential apparent diffusion coefficients in prostate cancer. Magn Reson Imaging 2009;27(3):355-359.
31. Mulkern RV, Barnes AS, Haker SJ, et al. Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range. Magn Reson Imaging 2006;24(5):563-568. (Pubitemid 43776563)
32. Katahira K, Takahara T, Kwee TC, et al. Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. Eur Radiol 2011;21(1):188-196.
33. Kim CK, Park BK, Kim B. High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm2. AJR Am J Roentgenol 2010;194(1):W33-W37.
34. Haider MA, van der Kwast TH, Tanguay J, et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007;189(2):323-328. (Pubitemid 47195916)
35. Lim HK, Kim JK, Kim KA, Cho KS. Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection-a multireader study. Radiology 2009;250(1):145-151.
36. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29(9):1228-1242. (Pubitemid 41232997)
37. Epstein JI. What's new in prostate cancer disease assessment in 2006? Curr Opin Urol 2006;16(3):146-151. (Pubitemid 43791782)
38. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90(10):766-771. (Pubitemid 28259189)
39. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17(5):1499-1507. (Pubitemid 29220858)
40. Zelhof B, Pickles M, Liney G, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 2009;103(7):883-888.
41. Wang XZ, Wang B, Gao ZQ, et al. Diffusionweighted imaging of prostate cancer: correlation between apparent diffusion coefficient values and tumor proliferation. J Magn Reson Imaging 2009;29(6):1360-1366.
42. Bourne R, Kurniawan N, Cowin G, Sved P, Watson G. 16 T diffusion microimaging of fixed prostate tissue: preliminary findings. Magn Reson Med 2011;66(1):244-247.
43. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988;168(2):497-505.
44. Sigmund EE, Cho GY, Kim S, et al. Intravoxel incoherent motion imaging of tumor microenvironment in locally advanced breast cancer. Magn Reson Med 2011;65(5):1437-1447.
45. Yamada I, Aung W, Himeno Y, Nakagawa T, Shibuya H. Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 1999;210(3):617-623. (Pubitemid 29124018)
46. Chandarana H, Lee VS, Hecht E, Taouli B, Sigmund EE. Comparison of biexponential and monoexponential model of diffusion weighted imaging in evaluation of renal lesions: preliminary experience. Invest Radiol 2011;46(5):285-291.
47. Wang Z, Su MY, Najafi A, Nalcioglu O. Effect of vasodilator hydralazine on tumor microvascular random flow and blood volume as measured by intravoxel incoherent motion (IVIM) weighted MRI in conjunction with Gd-DTPA-albumin enhanced MRI. Magn Reson Imaging 2001;19(8):1063-1072.
48. Riches SF, Hawtin K, Charles-Edwards EM, de Souza NM. Diffusion-weighted imaging of the prostate and rectal wall: comparison of biexponential and monoexponential modelled diffusion and associated perfusion coefficients. NMR Biomed 2009;22(3):318-325.
49. Döpfert J, Lemke A, Weidner A, Schad LR. Investigation of prostate cancer using diffusion-weighted intravoxel incoherent motion imaging. Magn Reson Imaging 2011;29(8):1053-1058.
50. Yuen S, Yamada K, Goto M, Nishida K, Takahata A, Nishimura T. Microperfusioninduced elevation of ADC is suppressed after contrast in breast carcinoma. J Magn Reson Imaging 2009;29(5):1080-1084.
51. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27(26):4300-4305.
52. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 2005;23(28):6992-6998.
53. Wright JL, Salinas CA, Lin DW, et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort. J Urol 2009;182(6):2702-2707.
54. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-1328.
55. Freedland SJ, Amling CL, Terris MK, et al. Is there a difference in outcome after radical prostatectomy between patients with biopsy Gleason sums 4, 5, and 6? results from the SEARCH database. Prostate Cancer Prostatic Dis 2003;6(3):261-265. (Pubitemid 37185158)
56. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169(2):517-523. (Pubitemid 36132976)
57. Graefen M, Karakiewicz PI, Cagiannos I, et al. A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol 2002;7(4):141-146.
58. Graefen M, Karakiewicz PI, Cagiannos I, et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2002;20(15):3206-3212. (Pubitemid 34831516)
59. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59(1):61-71.
60. Langer DL, van der Kwast TH, Evans AJ, et al. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 2008;249(3):900-908.
61. Reeder SB, Wintersperger BJ, Dietrich O, et al. Practical approaches to the evaluation of signal-to-noise ratio performance with parallel imaging: application with cardiac imaging and a 32-channel cardiac coil. Magn Reson Med 2005;54(3):748-754. (Pubitemid 41233774)
62. Heverhagen JT. Noise measurement and estimation in MR imaging experiments. Radiology 2007;245(3):638-639. (Pubitemid 350127334)